ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2022
Sympathetic activation in heart failure
Article in European heart journal supplements : journal of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 63 citations in OpenAlex.
- Stellate ganglion block for ventricular arrhythmia disease states: Emerging treatment options.Journal of anesthesia and translational medicine · 2026Review
- An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- Pleiotropic effects of renal denervation beyond blood pressure reduction.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Cardiorenal Hemodynamic Coupling: Mechanical Circulatory Support Augments Renal Blood Flow via Renal Vasodilation.JACC. Basic to translational science · 2026Article
- Impact of heart rate trajectories on mortality in critically Ill patients with atrial fibrillation and heart failure: a longitudinal cohort study.BMC cardiovascular disorders · 2026Article
- The clinical value of circadian biofeedback in chronic heart failure.European heart journal. Digital health · 2026Article
- Intensive blood pressure control in heart failure with preserved ejection fraction: a symptom-modifying strategy.Heart failure reviews · 2026Review
- Balancing the autonomic scale: the promise of transcutaneous vagus nerve stimulation in combating cardiovascular diseases.Frontiers in physiology · 2026Review
- Exploring the Role of Nesprin1 in isoproterenol-induced heart failure: Insights into pathogenesis and therapeutic implications.PloS one · 2026Article
- Effect of tofogliflozin on cardiac sympathetic nerve activity in type 2 diabetes mellitus patients with heart failure (TARGET-HF): rationale and design of the single-arm intervention trial.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Chronic heart failure and heart transplantation: The relationship between autonomic function and cardiac performance.World journal of transplantation · 2025Review
- GLP-1 Receptor Agonists in Heart Failure.Biomolecules · 2025Review
- Impact of non-cardiovascular factors on cardiovascular death in acute decompensated heart failure: Enhancing predictive models with frailty and comorbid constipation-the Constipation and Frailty Augmented AHEAD score.Geriatrics & gerontology international · 2025Article
- The neuronal imaging in cardiology: 123I-Biophysical reviews · 2025Review
- Modification of associations between ambient PMEnvironmental health : a global access science source · 2025Observational
- Neuroimmune Interactions and Their Role in Immune Cell Trafficking in Cardiovascular Diseases and Cancer.International journal of molecular sciences · 2025Review
- Trajectory of Cardiogenic Dementia: A New Perspective.Journal of cellular and molecular medicine · 2025Review
- Renal nerves in physiology, pathophysiology and interoception.Nature reviews. Nephrology · 2025Review
- Pharmacodynamics of single-dose omecamtiv mecarbil administered intravenously in clinically healthy cats.Open veterinary journal · 2024Article
- Early experience with baroreflex activation therapy from a vascular surgery perspective.Journal of vascular surgery cases and innovative techniques · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sympathetic activation has been long appreciated exclusively as a fundamental compensatory mechanism of the failing heart and, thus, welcome and to be supported. In the initial clinical phases of heart failure (HF), the sympathetic nervous system overdrive plays a compensatory function aimed at maintaining an adequate cardiac output despite the inotropic dysfunction affecting the myocardium. However, when the sympathetic reflex response is exaggerated it triggers a sequence of unfavourable remodelling processes causing a further contractile deterioration that unleashes major adverse cardiovascular consequences, favouring the HF progression and the occurrence of fatal events. Eventually, the sympathetic nervous system in HF was demonstrated to be a 'lethality factor' and thus became a prominent therapeutic target. The existence of an effective highly specialized intracardiac neuronal network immediately rules out the old concept that sympathetic activation in HF is merely the consequence of a drop in cardiac output. When a cardiac damage occurs, such as myocardial ischaemia or a primary myocardial disorder, the adaptive capability of the system may be overcame, leading to excessive sympatho-excitation coupled with attenuation till to abolishment of central parasympathetic drive. Myocardial infarction causes, within a very short time, both a functional and anatomical remodelling with a diffuse up-regulation of nerve growth factor (NGF). The subsequent nerve sprouting signal, facilitated by a rise in the levels of NGF in the left stellate ganglion and in the serum, triggers an increase in cardiac nerve density in both peri-infarct and non-infarcted areas. Finally, NFG production decreases over time, supposedly as an adaptative response to the prolonged exposure to sympathetic overactivity, leading in the end to a reduction in sympathetic nerve density. Accordingly, NGF levels were markedly reduced in patients with severe congestive heart failure. The kidney is the other key player of the sympathetic response to HF as it indeed reacts to under-perfusion and to loop diuretics to preserve filtration at the cost of many pathological consequences on its physiology. This vicious loop ultimately participates to the chronic and disruptive sympathetic overdrive. In conclusion, sympathetic activation is the natural physiological consequence to life stressors but also to any condition that may harm our body. It is the first system of reaction to any potential life-threatening event. However, in any aspect of life over reaction is never effective but, in many instances, is, actually, life threatening. One for all is the case of ischaemia-related ventricular fibrillation which is, strongly facilitated by sympathetic hyperactivity. The take home message? When, in a condition of harm, everybody is yelling failure is just around the corner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.